A study published in The Oncologist concluded that discrepant variant classification in public databases can introduce uncertainty and diminish patient care.
Can we trust gene variant information generated by public databases? A study published in The Oncologist concludes that discrepant variant classification in public databases can introduce uncertainty and diminish patient care.
Researchers at Northwestern University compared variant classifications obtained from a reference laboratory and from the public database ClinVar, a public archive of reports on human genotypic and phenotypic variations. Being a open access database, researchers can freely submit their clinical observations on genetic information on patient samples and the observed phenotype resulting from the genetic variance. Following processing of the submitted information, ClinVar makes the data available to interactive users as well as those wishing to use ClinVar in daily workflows and other local applications.
For their study, the researchers at Northwestern obtained variant classifications of BRCA1 and BRCA2 from ClinVar, which were then compared with the classification by a reference laboratory. Concordance and discordance were determined for variants whose ClinVar entries were of the same pathogenicity—pathogenic, benign, or uncertain. In case of a conflict, partial concordance was assumed “if ≥1 of the listed classifications agreed with the reference laboratory classification,” the authors note.
Of the more than 4200 unique BRCA variants that were studied, less than three-fourths (73.2%) were fully concordant, and 12.3% were partially concordant. A majority of the 14.5% variants with discordant classifications had a definitive classification (pathogenic or benign) from the reference laboratory compared with an uncertain classification in ClinVar.
Such discrepancy can have far-reaching consequences on treatment decisions, if physicians use such databases to interpret genetic test results on their patients’ tumor samples. According to the authors, a great deal of expertise and time investment may be needed for clinicians to research these discordant classifications and “calls into question the practicality of checking all test results against a database.” They also warn against using such databases for clinical interpretation of test results.
“The high degree of discordance seen in this study signals a cautionary note," senior study author William Gradishar, MD, said in a press release. "As a repository of actual patient results, it means that different labs are providing different results to patients for the same genetic mutation. By definition, this means that some patients are receiving incorrect results that may have life-changing or -threatening implications.”
Reference
Gradishar W, Johnson K, Brown K, Mundt E. Manley S. Clinical variant classification: a comparison of public databases and a commercial testing laboratory [published online April 13, 2017]. Oncologist. pii: theoncologist.2016-0431. doi: 10.1634/theoncologist.2016-0431.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bridging Cancer Care Gaps and Overcoming Medical Mistrust
November 13th 2024In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
Read More
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More